The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group receiving only supportive care. Rash was seen in 255 of the patients treated with cetuximab.

Those with any skin toxicity had an ORR of 25.8% in the combination arms and 13% in the cetuximab-alone arm. [22] In the study conducted by Lenz et al, the severity of rash was strongly related to ...

Indeed, results from the FLEX trial demonstrate that cetuximab in combination with platinum-based chemotherapy is a new treatment strategy for patients with advanced NSCLC. The EGFR pathway has an ...

In patients who develop serious infusion reactions, cetuximab should be discontinued immediately and permanently. The most common side effect is acneiform rash, which should be treated according ...

Erbitux (cetuximab) is a prescription drug that’s used to treat certain types of cancer. The drug comes as a solution that’s given through a vein by a healthcare professional. It’s usually ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...